PE20142182A1 - Inhibidores de iap - Google Patents

Inhibidores de iap

Info

Publication number
PE20142182A1
PE20142182A1 PE2014001069A PE2014001069A PE20142182A1 PE 20142182 A1 PE20142182 A1 PE 20142182A1 PE 2014001069 A PE2014001069 A PE 2014001069A PE 2014001069 A PE2014001069 A PE 2014001069A PE 20142182 A1 PE20142182 A1 PE 20142182A1
Authority
PE
Peru
Prior art keywords
iap inhibitors
refers
compound
iap
inhibitors
Prior art date
Application number
PE2014001069A
Other languages
English (en)
Spanish (es)
Inventor
Frederick Cohen
Lewis J Gazzard
Vickie Hsiao-Wei Tsui
John A Flygare
Original Assignee
Curis Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc, Genentech Inc filed Critical Curis Inc
Publication of PE20142182A1 publication Critical patent/PE20142182A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PE2014001069A 2012-01-03 2013-01-03 Inhibidores de iap PE20142182A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03

Publications (1)

Publication Number Publication Date
PE20142182A1 true PE20142182A1 (es) 2015-01-16

Family

ID=48695302

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001069A PE20142182A1 (es) 2012-01-03 2013-01-03 Inhibidores de iap

Country Status (41)

Country Link
US (6) US8716236B2 (OSRAM)
EP (2) EP3133073B1 (OSRAM)
JP (2) JP5747137B2 (OSRAM)
KR (3) KR101553792B1 (OSRAM)
CN (2) CN104159897A (OSRAM)
AR (2) AR089623A1 (OSRAM)
AU (1) AU2013202780B2 (OSRAM)
BR (1) BR112014016637B1 (OSRAM)
CA (1) CA2861637C (OSRAM)
CL (1) CL2014001770A1 (OSRAM)
CO (1) CO7020915A2 (OSRAM)
CR (1) CR20140367A (OSRAM)
CY (2) CY1118371T1 (OSRAM)
DK (2) DK3133073T3 (OSRAM)
EC (1) ECSP14011792A (OSRAM)
ES (2) ES2594856T3 (OSRAM)
HK (1) HK1203949A1 (OSRAM)
HR (2) HRP20161381T1 (OSRAM)
HU (2) HUE037760T2 (OSRAM)
IL (2) IL242314A (OSRAM)
LT (2) LT2800749T (OSRAM)
MA (1) MA35895B1 (OSRAM)
ME (2) ME02526B (OSRAM)
MX (1) MX336294B (OSRAM)
MY (1) MY178390A (OSRAM)
NO (1) NO2755614T3 (OSRAM)
NZ (1) NZ627480A (OSRAM)
PE (1) PE20142182A1 (OSRAM)
PH (2) PH12014501534B1 (OSRAM)
PL (2) PL2800749T3 (OSRAM)
PT (2) PT3133073T (OSRAM)
RS (2) RS55327B1 (OSRAM)
RU (2) RU2728789C2 (OSRAM)
SG (1) SG11201403784QA (OSRAM)
SI (2) SI2800749T1 (OSRAM)
SM (2) SMT201800352T1 (OSRAM)
TR (1) TR201808088T4 (OSRAM)
TW (1) TWI503318B (OSRAM)
UA (1) UA114417C2 (OSRAM)
WO (1) WO2013103703A1 (OSRAM)
ZA (1) ZA201405535B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (OSRAM) 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
IL274598B2 (en) 2017-11-13 2025-01-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd SMAC mimetics used as IAP inhibitors and their use
CN112533898A (zh) 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
US20230029259A1 (en) * 2019-12-02 2023-01-26 Ascentage Pharma (Suzhou) Co., Ltd. Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2022463015A1 (en) 2021-10-22 2024-05-09 Tract Pharmaceuticals, Inc. Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CN117110469B (zh) * 2023-08-18 2025-12-09 中国检验检疫科学研究院 一种测定防脱发类化妆品中禁用组分的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE69830577T2 (de) 1997-04-15 2006-05-04 Genentech, Inc., South San Francisco Halo-alkoxycarbonylverbindungen
CA2570321C (en) * 2004-07-02 2013-10-08 Genentech, Inc. Inhibitors of iap
KR20120127754A (ko) * 2004-12-20 2012-11-23 제넨테크, 인크. Iap의 피롤리딘 억제제
US8044209B2 (en) 2006-10-12 2011-10-25 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
NZ598890A (en) 2007-04-30 2013-10-25 Genentech Inc Inhibitors of iap
NO2755614T3 (OSRAM) * 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Also Published As

Publication number Publication date
BR112014016637A2 (pt) 2017-06-13
CL2014001770A1 (es) 2015-04-17
UA114417C2 (uk) 2017-06-12
EP3133073B1 (en) 2018-05-02
EP3133073A3 (en) 2017-03-22
ME03084B (me) 2019-01-20
HK1203949A1 (en) 2015-11-06
EP2800749B1 (en) 2016-09-21
RU2728789C2 (ru) 2020-07-31
PT2800749T (pt) 2016-10-24
DK2800749T3 (en) 2016-11-07
HUE037760T2 (hu) 2018-09-28
NO2755614T3 (OSRAM) 2018-03-31
ME02526B (me) 2017-02-20
KR101553792B1 (ko) 2015-09-16
KR20180051646A (ko) 2018-05-16
MA35895B1 (fr) 2014-12-01
PH12014501534A1 (en) 2014-10-08
US9586991B2 (en) 2017-03-07
RU2016124658A (ru) 2018-12-04
CA2861637C (en) 2017-07-18
TR201808088T4 (tr) 2018-06-21
LT3133073T (lt) 2018-06-25
CN104159897A (zh) 2014-11-19
JP5747137B2 (ja) 2015-07-08
RU2593259C2 (ru) 2016-08-10
KR20140107670A (ko) 2014-09-04
PH12015501038B1 (en) 2015-09-21
US11963994B2 (en) 2024-04-23
HRP20180976T1 (hr) 2018-08-10
US20160102119A1 (en) 2016-04-14
EP3133073A2 (en) 2017-02-22
MX2014007895A (es) 2015-03-19
US20170136084A1 (en) 2017-05-18
US20220211797A1 (en) 2022-07-07
JP2015504072A (ja) 2015-02-05
AR089623A1 (es) 2014-09-03
BR112014016637B1 (pt) 2022-06-14
US9238675B2 (en) 2016-01-19
ZA201405535B (en) 2017-08-30
RS55327B1 (sr) 2017-03-31
PL3133073T3 (pl) 2018-09-28
US11096982B2 (en) 2021-08-24
BR112014016637A8 (pt) 2017-07-04
RU2016124658A3 (OSRAM) 2019-09-09
US20190224269A1 (en) 2019-07-25
MY178390A (en) 2020-10-12
NZ627480A (en) 2016-04-29
KR101917992B1 (ko) 2018-11-13
CY1118371T1 (el) 2017-06-28
CY1120355T1 (el) 2019-07-10
CR20140367A (es) 2015-02-18
US8716236B2 (en) 2014-05-06
HRP20161381T1 (hr) 2016-12-02
EP2800749A1 (en) 2014-11-12
MX336294B (es) 2016-01-14
CO7020915A2 (es) 2014-08-11
ES2672809T3 (es) 2018-06-18
CN107915728A (zh) 2018-04-17
CA2861637A1 (en) 2013-07-11
PT3133073T (pt) 2018-06-18
US20140235551A1 (en) 2014-08-21
DK3133073T3 (en) 2018-06-18
SG11201403784QA (en) 2014-08-28
AU2013202780B2 (en) 2015-04-16
US20130172264A1 (en) 2013-07-04
TW201333001A (zh) 2013-08-16
CN107915728B (zh) 2021-04-30
RS57438B1 (sr) 2018-09-28
KR20150065960A (ko) 2015-06-15
KR101855566B1 (ko) 2018-05-04
EP2800749A4 (en) 2015-08-05
SMT201600357B (it) 2016-11-10
SI2800749T1 (sl) 2016-11-30
AR123542A2 (es) 2022-12-14
TWI503318B (zh) 2015-10-11
WO2013103703A1 (en) 2013-07-11
IL242314A (en) 2016-08-31
SMT201800352T1 (it) 2018-09-13
ES2594856T3 (es) 2016-12-23
HUE031305T2 (hu) 2017-07-28
RU2014130171A (ru) 2016-02-27
PL2800749T3 (pl) 2017-01-31
AU2013202780A1 (en) 2013-07-18
IL233386A0 (en) 2014-08-31
JP2015199738A (ja) 2015-11-12
LT2800749T (lt) 2016-10-25
PH12015501038A1 (en) 2015-09-21
IL233386A (en) 2016-08-31
PH12014501534B1 (en) 2014-10-08
ECSP14011792A (es) 2015-12-31
SI3133073T1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
CR20140405A (es) Apoptosis señal reguladores del inhibidor de quinasa
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CR20150416A (es) Inhibidores de cdc7
PE20150887A1 (es) Compuestos de benceno sustituidos
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
ES2570976T3 (es) Derivado de 2,4-diaminopirimidina bicíclico condensado como inhibidor dual de ALK y FAK
CR20150447A (es) Nuevos derivados de pirazol
GT201400090A (es) 2-tiopirimidinonas
CR20150204A (es) Nuevos derivados de piridina
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
CO7020915A2 (es) Inhibidores de iap
EA201690561A1 (ru) Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
BR112015019624A2 (pt) quinazolinas como inibidores de quinase
CR20160448A (es) Nuevos derivados de piridina
BR112016028022A2 (pt) compostos de sulfonamida e seus usos como inibidores de stat5
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
CU20150173A7 (es) COMPOSICIÓN FARMACÉUTICA QUE INCLUYE UN INHIBIDOR DE LA HMG-Coa REDUCTASA QUE MINIMIZA LA INTERACCIÓN DEL ÁCIDO ÁCIDO ACETILSALICÍLICO CON LA ESTATINA
BR112014019220A8 (pt) Novos derivados de pirrolidina
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa

Legal Events

Date Code Title Description
FG Grant, registration